LAI Usage in Complex Mental Health Conditions: Why and When to Initiate

Target Audience

This activity is intended for physicians (psychiatrists and general practitioners), advanced practice providers, nurses, pharmacists and other healthcare professionals who manage patients with severe mental health disorders, such as schizophrenia and bipolar disorder.

Overview

This educational activity is designed to enhance clinicians’ ability to discuss, select and administer personalized LAI treatment strategies to patients with severe mental health conditions such as schizophrenia and bipolar disorder.

Educational Objectives

Upon completion of the activities in this initiative, learners should be able to:

• Evaluate strategies to improve medication adherence and treatment outcomes in schizophrenia and bipolar disorder for inclusion into your clinical practice.
• Critique the evidence supporting the use of second generation long-acting injectable (LAI) antipsychotics early in the course of illness.

Faculty

Joseph F. Goldberg, MD
Clinical Professor of Psychiatry
Icahn School of Medicine at Mount Sinai

John Kane, MD
Professor of Psychiatry and Molecular Medicine
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Co-Director, Institute of Behavioral Science
Feinstein Institutes for Medical Research

Financial Support

This activity is supported by an independent educational grant from Indivior Inc.; Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC; Lundbeck and Otsuka America Pharmaceutical, Inc.

Providers

Jointly provided by Partners for Advancing Clinical Education and Novus Medical Education.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Novus Medical Education. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Education
PACE designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.5 contact hours.

Pharmacy Continuing Education
PACE designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008073-9999-24-119-H01-P)
Type of Activity: Knowledge
For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.

Disclosure of Conflicts of Interest

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Dr. Goldberg:
Speaker/Speakers' Bureau: AbbVie, Alkermes, Axsome, Intra-Cellular Therapies
Advisor/Consultant: Genomind, Luye Pharmaceuticals, Neurelis, Neuroma, Otsuka, Sunovion, Supernus

Dr. Kane:
Advisor/Consultant: Alkermes, Allergan, Boehringer-Ingelheim, Cerevel, Click Therapeutics, Lundbeck, HealthRhythms, HLS Therapeutics, Indivior, Intra-Cellular Therapies, Janssen Pharmaceuticals, Inc., Johnson & Johnson, Karuna Therapeutics, LB Pharmaceuticals, Merck, Minerva, Neurocrine Biosciences, Newron, Novartis, NW PharmaTech, Otsuka, Roche, Saladax, Sumitomo Pharma Co., Teva
Research Support: Lundbeck, Janssen, Otsuka, Sumitomo Pharma Co.
Stock/Stock Options: Cerevel, Karuna, LB Pharmaceuticals, North Shore Therapeutics, HealthRhythms

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

Method of Participation

There are no fees for participating and receiving CME credit for this activity. To claim credit, participants must complete the following:

1. Review the target audience, accreditation information, learning objectives and faculty disclosures.
2. Complete the pre-test (if one exists).
3. View and digest the educational content in its entirety.
4. Complete the post-test and activity evaluation.
5. Physicians who receive a grade of 75% or better on the post-test and complete the evaluation will receive a Statement of Credit.
6. All other participants who receive a grade of 75% or better on the post-test and complete the evaluation will receive a Certificate of Participation.

We encourage you to complete the Activity Evaluation to provide feedback for future programming. After submitting the evaluation, you may download the certificate immediately from the confirmation page or afterward by clicking the Download Certificate button in your confirmation email. Records of all CME/CE activities completed can be found on the "My CMEstream" page.    

CME Provider

For additional information about the accreditation of this activity, please contact PACE at contactus@partnersed.com

System Requirements

This site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended. We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Firefox, Chrome, Safari or Edge.